Comparing XWELL and Bausch + Lomb

Two medical companies with different strengths and weaknesses

Published on Feb. 16, 2026

Got story updates? Submit your updates here. ›

XWELL (NASDAQ:XWEL) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which one is the better business? The article compares the two companies based on factors like analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, and risk.

Why it matters

Investors looking to invest in the medical industry may be interested in understanding the differences between these two companies to determine which one aligns better with their investment goals and risk tolerance.

The details

The analysis shows that Bausch + Lomb has stronger institutional ownership, lower insider ownership, higher revenue, and a lower price-to-earnings ratio compared to XWELL. Bausch + Lomb also has a stronger consensus rating from analysts and a higher potential upside. However, XWELL has higher earnings and its stock is more volatile than Bausch + Lomb's.

  • The article was published on February 16, 2026.

The players

XWELL, Inc.

A company that provides health and wellness services in airport and off-airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat.

Bausch + Lomb Corporation

An eye health company that operates in three segments: Vision Care, Pharmaceuticals, and Surgical. It provides contact lenses, eye care products, and medical devices for eye conditions.

Got photos? Submit your photos here. ›

The takeaway

Investors evaluating these two medical companies should consider factors like institutional ownership, valuation, analyst ratings, and risk profile to determine which one aligns better with their investment strategy and risk tolerance.